An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase I Study With Cabazitaxel Administered as a 1-hour Intravenous Infusion Every 3 Weeks in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer.

Trial Profile

An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase I Study With Cabazitaxel Administered as a 1-hour Intravenous Infusion Every 3 Weeks in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Cabazitaxel (Primary) ; Prednisolone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Sanofi; Sanofi K.K.
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 28 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top